BPC-157 vs KPV
BPC-157 is a synthetic pentadecapeptide whose sequence corresponds to a fragment of a protein found in gastric juice, and its literature is overwhelmingly rodent work on tendon, ligament, muscle and gastrointestinal injury. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13), and its literature is concentrated in gut inflammation, where uptake through the PepT1 di- and tripeptide transporter reduces colitis severity in rodent models, and in keratinocyte and barrier-protective work. The two are habitually paired because both are promoted for gut healing and inflammation. No published study has administered both, tested one against the other, or compared them in any model. A PubMed search for the two compounds together, under any combination of trade name, sequence and code designation, returns no records at all. Two 2026 papers name both without dosing either. Every side-by-side claim made about these peptides elsewhere is therefore an editorial juxtaposition of two separate literatures rather than a finding from a shared experiment.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No study has tested BPC-157 and KPV against each other, or administered both within one design, in any species or model system. Repeated PubMed searches combining BPC-157, BPC 157, BPC157 and body protection compound with KPV, Lys-Pro-Val, lysine-proline-valine, alpha-MSH and alpha-melanocyte-stimulating hormone returned zero records in title and abstract fields. Europe PMC full-text search located only two publications that name both compounds anywhere in the text, and neither administered either peptide. The first is a 2026 narrative review of therapeutic peptides that groups BPC-157 and KPV in a shared regenerative and tissue-repair category and summarises the separate mechanistic literature for each. The second is a 2026 content analysis of Crohn disease videos on a social platform, which records the promotion of BPC-157 and KPV as treatments for inflammatory bowel disease as an example of non-standard therapeutic content and notes that neither is approved for human consumption. Any comparison between the two peptides is consequently indirect, assembled from separate studies that used different species, different disease models, different routes of delivery and different endpoints.
The 2 publications that cover both
- 01Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · Int J Mol Sci · narrative review of 106 articles retrieved from PubMed, ScienceDirect and SciELO, prioritising systematic reviews, meta-analyses and randomised controlled trials
The review placed BPC-157 and the Lys-Pro-Val tripeptide in one regenerative and tissue-repair category alongside thymosin beta-4, thymosin alpha-1 and GHK-Cu. It described BPC-157 as a 15-amino-acid peptide originally isolated from gastric juice and notable for stability in gastric acid, and KPV as an alpha-MSH-derived tripeptide taken up by intestinal epithelial and immune cells through the PepT1 transporter, where it suppresses NF-kappaB and MAPK signalling and lowers pro-inflammatory cytokine levels. The authors concluded that further study is required before most of these peptides can be used safely in humans. Neither compound was administered.
- 02Review2026
Scrolling for science: Assessing the quality and accuracy of Crohn's disease-related content on Instagram reels
Madabhushi S, et al. · PLoS One · cross-sectional content analysis of 78 top-viewed English-language videos tagged with a Crohn disease hashtag, each scored independently by two reviewers using an adapted harm and benefit score and JAMA benchmark criteria
The analysis catalogued the promotion of BPC-157, KPV and larazotide as effective treatments for inflammatory bowel disease, irritable bowel syndrome and coeliac disease under the heading of non-standard therapeutic strategies, and recorded that these substances are not approved by the United States Food and Drug Administration for human consumption. Videos offering medical advice carried the lowest median harm and benefit score of any content type, and 42 percent of videos judged harmful had been created by medical professionals. No peptide was administered.
Side by side.
| BPC-157 | KPV | |
|---|---|---|
| Evidence maturity | Preclinical only | Preclinical only |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 8 | 6 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A synthetic 15-amino-acid peptide whose sequence corresponds to a fragment of a protein found in gastric juice. It has no confirmed endogenous circulating counterpart of its own. | The C-terminal tripeptide of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13), a three-residue sequence that occurs within a well-characterised endogenous hormone. |
| Mechanism as described in the literature | Preclinical work attributes effects to angiogenesis associated with VEGFR2 activation and upregulation, and to modulation of the nitric oxide system, with additional cytoprotective and gut-barrier effects reported in rodents. | Uptake into intestinal epithelial and immune cells through the PepT1 di- and tripeptide transporter, followed by suppression of NF-kappaB and MAPK signalling and reduced pro-inflammatory cytokine output. One study separated the anti-inflammatory action from MC1R signalling. |
| Size and character of the evidence base | Several hundred rodent studies across tendon, ligament, muscle, gastrointestinal and ischaemia-reperfusion injury, though much of the corpus originates from a small number of closely affiliated research groups, which limits independent replication. | A smaller, entirely preclinical literature concentrated in murine and rat colitis, keratinocyte culture and, more recently, adipocyte and hepatocyte models. A substantial share of the recent output is formulation science rather than new pharmacology. |
| Best-characterised finding | Healing of surgically created defects in rats that do not heal spontaneously, including complete quadriceps transection, medial collateral ligament transection and myotendinous junction detachment. | Reduced intestinal inflammation in mouse colitis models, with the effect shown to depend on PepT1-mediated transport into epithelial and immune cells rather than on the full alpha-MSH sequence. |
| Human data | Two uncontrolled open-label pilot studies and one retrospective chart review, all from the same private clinic, plus one ex vivo study on surgically discarded human arterial tissue. No randomised controlled trial has been completed for any indication. | None. No human clinical trial of KPV has been published for colitis, wound healing, skin inflammation or any other indication, so effective human route and safety profile are unknown. |
| Evidence maturity | Preclinical only, with 2025 and 2026 systematic and narrative reviews in orthopaedic and sports medicine journals explicitly characterising the human evidence as insufficient. | Preclinical only, and at an earlier stage than BPC-157 in that no human study of any design has been published. |
| Stability and what was actually tested | Published rodent studies used the same pentadecapeptide that is sold, across intraperitoneal, per-oral and topical routes, so the literature and the marketed molecule describe one substance. | Free KPV was reported to be unstable on rectal administration, which compromised efficacy, and most recent work uses engineered delivery vehicles such as hyaluronic acid-functionalised nanoparticles, thermosensitive hydrogels and mucoadhesive gels. Results from those formulations do not transfer to the unformulated peptide. |
| Regulatory status and basis of marketing claims | No approved formulation in any jurisdiction, prohibited in professional sport, and identified in 2026 reviews as one of the peptides most heavily promoted outside regulatory oversight. | No approved formulation in any jurisdiction. Claims rest on rodent colitis data generated with targeted delivery systems and on the wider alpha-MSH and melanocortin literature rather than on studies of the plain tripeptide in humans. |
And what it does not.
Nothing in the published record establishes how these two peptides compare, because no experiment has ever run them side by side, and no paper has even administered both. What the separate literatures support is different in kind rather than in degree. BPC-157 has a large rodent corpus concentrated on structural repair of surgically created tendon, ligament and muscle defects, weak and uncontrolled human reports from a single clinic, and no completed randomised trial. KPV has a smaller corpus concentrated on inflammatory signalling in the gut, a defined transport mechanism through PepT1, and no human study of any design. Both are preclinical-only by the standard applied across this library. Two asymmetries cut against a simple ranking: the KPV work that produced the strongest colitis results used engineered delivery vehicles rather than the plain peptide sold to consumers, and the BPC-157 preclinical corpus has limited independent replication. A reader looking for a published basis to prefer one over the other for gut inflammation, wound healing or recovery will not find it in the literature as it stands.
Common questions.
- Has any experiment given both BPC-157 and KPV to the same animals?
No. Searches of PubMed combining every published name for each compound, including the sequence descriptions and code designations, return no records. Europe PMC full-text search finds only two 2026 papers that mention both anywhere in their text, and neither administered either peptide: one is a narrative review of therapeutic peptides and the other is a study of the quality of Crohn disease content on social media. There is no shared animal experiment, no shared cell model and no shared clinical dataset.
- Which of the two has more evidence specifically in gut inflammation?
The two literatures address gut inflammation differently. KPV has a focused set of rodent colitis studies, including dextran sodium sulfate and TNBS models and a colitis-associated cancer model, with the mechanism traced to PepT1-mediated uptake. BPC-157 has gastrointestinal and ischaemia-reperfusion work within a much larger corpus that is weighted toward musculoskeletal injury. Neither has a completed randomised human trial in any gastrointestinal condition, so neither literature supports a comparative claim about gut inflammation in people.
- Why does so much KPV research use nanoparticles and hydrogels?
Free KPV was reported to be unstable on rectal administration in a way that compromised efficacy, so published work increasingly delivers the tripeptide inside engineered vehicles, including hyaluronic acid-functionalised polymeric nanoparticles for oral targeting, self-cross-linked thiolated polyglutamic acid hydrogels, thermosensitive mucoadhesive gels and carrier-free self-assembled nanodrugs. Those studies test a formulation rather than the peptide alone, and the research entry for KPV in this library states plainly that their results do not transfer to unformulated peptide.
- Do the two papers that name both compounds support using either one?
Neither does. The 2026 narrative review of therapeutic peptides grouped both in a regenerative category, summarised the preclinical mechanism claimed for each, and concluded that further study is needed before most of these peptides can be used safely in humans. The social media content analysis cited both as examples of non-standard therapies promoted for inflammatory bowel disease, and recorded that the substances are not approved by the United States Food and Drug Administration for human consumption.
- Is either peptide closer to a completed clinical trial?
BPC-157 is marginally further along in that human reports exist at all, but they are two uncontrolled open-label pilot studies and one retrospective chart review, all from a single private clinic and none with a control group or blinding. KPV has no published human study of any design, including no safety study. Neither compound has a completed randomised controlled trial, an established human route or long-term human safety data, and neither is approved in any jurisdiction.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.